What was the temper like at an enormous gene remedy convention final week? Why is Novo Nordisk’s CEO stepping down? And why has Adam been in such a great temper?
We focus on all that and extra on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about M&A offers selecting up, management adjustments at Novo, and up to date FDA advisory committee conferences for most cancers medication.
We additionally deliver on STAT reporter Jason Mast to speak concerning the newest analysis and sentiment on the annual American Society of Cell and Gene Remedy assembly.
For extra on the promising outcomes of a customized gene remedy offered at ASCGT, go right here; for extra on scientists’ reluctance to debate new FDA regulator Vinay Prasad on the assembly, go right here; to learn extra on the enterprise overhaul on the gene modifying firm Prime Medicines, go right here; and to be taught extra the adjustments at Novo, go right here.
Make certain to join “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.
